GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
Stockhead on MSN7h
Closing Bell: Tech leads and goldies hit hard; Variscan jumps 50pc as Spanish zinc drilling beginsThe ASX rose, driven by gains in Xero, while gold stocks slid. Meanwhile Variscan surged 50% and Bitcoin briefly hit ... Read ...
The ASX rises on positive US inflation news, Xero ticks up 5% and Bitcoin hits US$93k before cooling off a tad.
LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...
The study will be run at approximately 40 sites with some 150 subjects. Progression-free survival or PFS will be the primary ...
Longer survival was seen in those with melanoma who received programmed cell death receptor-1 or its ligand who had a low neutrophil-lymphocyte ratio.
The company recorded a median progression-free survival duration of 5.3 months. All patients experienced treatment-emergent ...
The following is a summary of "Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic ...
Hand-in-hand with overall survival, CARVYKTI has also maintained significant improvement in progression-free survival as ...
The primary end point they were looking for was stringent complete response [CR]. At the end of the treatment evaluation, ...
The median progression-free survival was 6.8 months, and the median overall survival was 19.1 months. Pegylated liposomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback